370864-42-9

Basic information

• Product Name: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate;1(2H)-Pyridinecarboxylic acid, 4-(3-cyanophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester
• CAS NO: 370864-42-9
• Molecular Formula: C₁₇H₂₀N₂O₂
• Molecular Weight: 284.3529
• Mol File: 370864-42-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(370864-42-9)
• EPA Substance Registry System: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(370864-42-9)

Safety Data

• Hazardous Substances Data: 370864-42-9(Hazardous Substances Data)

Upstream product

• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 150255-96-2 (3‐cyanophenyl)boronic acid 
• 6952-59-6 3-cyanobromobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 375853-96-6 4-(3-Cyano-phenyl)-4-hydroxy-piperidine-1-carboxylic acid-tert-butyl ester 
• 1386393-97-0 tert-butyl 4-[(1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 1290053-82-5 [3-(2-{4-[3-(aminomethyl)phenyl]piperidin-1-yl}-2-oxoethyl)phenyl]boronic acid 
• 1290056-55-1 tert-butyl 4-(3-((((benzyloxy)carbonyl)amino)methyl)phenyl)piperidine-1-carboxylate 
• 1290056-56-2 benzyl N-[[3-(4-piperidyl)phenyl]methyl]carbamate 
• 1290056-57-3 benzyl 3-(1-(2-(3,4-dihydroxyphenyl)acetyl)piperidin-4-yl)benzylcarbamate 
• 1290056-75-5 benzyl 3-(1-(2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetyl)piperidin-4-yl)benzylcarbamate 
• 1574730-95-2 3-(1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 1574730-70-3 3-(1-(2-aminoethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 1394387-86-0 3-(1-(2-((3-isopropylisoxazol-5-yl)methylamino)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 370864-72-5 3-(piperidin-4-yl)-benzonitrile 
• 1290056-76-6 benzyl 3-(1-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetyl)piperidin-4-yl)benzylcarbamate 
• 1290053-74-5 1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-2-(3,4-dihydroxyphenyl)ethanone hydrochloride 
• 1290056-54-0 tert-butyl 4-(3-(aminomethyl)phenyl)piperidine-1-carboxylate 
• 370864-73-6 tert-butyl 4-(3-cyanophenyl)piperidine-1-carboxylate 

Relevant articles and documents

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS

Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.